NuCana plc
NCNA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for NCNA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NCNA
NuCana plc is a clinical-stage biopharmaceutical company developing ProTide therapeutics for cancer, with lead candidates NUC-7738 and NUC-3373 in early-phase trials and no approved products.
Key risk: No approved products
Market Cap
$7.3M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Tracking 4 clinical trials for NuCana plc.
NuCana plc is a clinical-stage biopharmaceutical company developing ProTide therapeutics for cancer, with lead candidates NUC-7738 and NUC-3373 in early-phase trials and no approved products.
- NuCana is focused on developing its proprietary ProTide technology platform, with lead candidates NUC-7738 and NUC-3373 in early-stage clinical trials [sec · filed 2026-03-19].
- As of December 31, 2025, the company reported cash and cash equivalents of £24.3 million ($24.3M), shareholders' equity of $38.5M, and total debt of $0.7M [sec · filed 2026-03-19].
- The company has incurred recurring losses, with an accumulated deficit of £252.3 million and cash used in operating activities of £7.5 million for the year ended December 31, 2025 [sec · filed 2026-03-19].
- NuCana has no products that have gained marketing approval and does not currently generate any revenues from product sales [sec · filed 2026-03-19].
What works
- NuCana's proprietary ProTide technology platform is a key strategic asset, used to build a pipeline of product candidates including NUC-7738 and NUC-3373 [sec · filed 2026-03-19].
- The company has ongoing clinical trials: a Phase 1/2 trial (NuTide:701) evaluating NUC-7738 as monotherapy and in combination with pembrolizumab, and a Phase 1b/2 trial (NuTide:303) evaluating NUC-3373 [sec · filed 2026-03-19].
What to weigh
- NuCana is early in development with no approved products, making it difficult to assess future viability and revenue generation [sec · filed 2026-03-19].
- The company has a significant accumulated deficit of £252.3 million and expects expenses to increase, requiring substantial additional funding that may not be available on acceptable terms [sec · filed 2026-03-19].
- Early-stage clinical trial results may not be indicative of later-stage or final outcomes, and the risk of failure in drug development is high [sec · filed 2026-03-19].
From the filings
Quoted directly from source documents.
NuCana has no approved products and relies on successful development of its ProTides.
“We currently do not have any products that have gained marketing approval.”
SEC filings · March 19, 2026
The company has incurred significant losses and has a large accumulated deficit.
“We have incurred recurring losses from our operations, have an accumulated deficit totaling £252.3 million and cash flows used in operating activities of £7.5 million as of and for the year ended December 31, 2025.”
SEC filings · March 19, 2026
NuCana's cash position as of December 31, 2025.
“We had cash and cash equivalents of £24.3 million at December 31, 2025.”
SEC filings · March 19, 2026
The company's lead candidates are in early-stage clinical trials.
“our product candidates: NUC-7738, which is being evaluated in a Phase1/2 clinical trial (NuTide:701) as a monothe”
SEC filings · March 19, 2026
Risks & what to watch (4)›
Key risks
- No approved products — NuCana has no marketed products and may never develop a commercializable product [sec · filed 2026-03-19].
- Substantial doubt as going concern — The company may face conditions that raise substantial doubt about its ability to continue as a going concern [sec · filed 2026-03-19].
- Need for additional funding — Requires substantial additional capital to complete development; funding may not be available on acceptable terms [sec · filed 2026-03-19].
- Clinical trial failure risk — Early-stage trial results may not predict later-stage success; drug development has high failure rates [sec · filed 2026-03-19].
What to watch
- Progress and data from the Phase 1/2 NuTide:701 trial evaluating NUC-7738 as monotherapy and in combination with pembrolizumab [sec · filed 2026-03-19].
- Updates from the Phase 1b/2 NuTide:303 trial evaluating NUC-3373 [sec · filed 2026-03-19].
- The company's ability to secure additional financing to support ongoing and future clinical development [sec · filed 2026-03-19].
- Any changes in the accumulated deficit and cash burn rate as indicators of financial runway [sec · filed 2026-03-19].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run NuCana plc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NuCana plc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
6
Total value held
$60K
| Holder | Shares | Value |
|---|---|---|
| glass jacobson investment advisors llc | 15,000 | $21K |
| citadel advisors llc | 13,855 | $20K |
| jane street group, llc | 10,511 | $15K |
| rhumbline advisers | 3,722 | $5K |
| morgan stanley | 2 | $3 |
| acadian asset management llc | 2 | $0 |
Short Interest
as of May 1, 2026- % of float
- 4.1%
- Days to cover
- 3.3
- Shares short
- 169,130
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NCNA short interestFrequently asked questions
What is the AI investment thesis for NuCana plc?
NuCana plc is a clinical-stage biopharmaceutical company developing ProTide therapeutics for cancer, with lead candidates NUC-7738 and NUC-3373 in early-phase trials and no approved products.
Who is the CEO of NuCana plc?
Mr. Hugh Stephen Griffith is the chief executive officer of NuCana plc (NCNA).
Where is NuCana plc headquartered?
NuCana plc (NCNA) is headquartered in Edinburgh, United Kingdom.
What therapeutic areas does NuCana plc focus on?
NuCana plc develops therapies across Oncology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.